20
Views
2
CrossRef citations to date
0
Altmetric
Special Report

Cost allocation in antihypertensive drug therapies

, , , , &
Pages 419-426 | Published online: 09 Jan 2014

References

  • SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in Elderly Program (SHEP). JAIVIA 265,3255–3264 (1991).
  • MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effect of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized clinical trials. Frog. Calrliovas. Dis.29, 99–118 (1996).
  • Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338, 1281–1285 (1991).
  • Thrift AG, McNeil JJ, Forbes A, Donnan GA. Three important subgroups of hypertensive persons at greater risk of intracerebral hemorrhage. Hypertension 31, 1223–1229 (1998).
  • Hansson L, Zanchetti A, Carruthers SG et al Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351,1755–1762 (1998).
  • Family Heart Study Group. Randomized controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. BE Med. 308,120–131 (1994).
  • Hypertension prevalence and the status of awareness, treatment and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension 7,457–468 (1985).
  • Medical Research Council Working Party (MRC). MRC trial of treatment of mild hypertension: Principal results. BE Med. J. 291, 97–104 (1985).
  • Jones JK, Gorkin L, Lian JR, Staffa JA, Fletcher AP. Discontinuation of and changes in the treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BE Med. J. 311,293-295 (1995).
  • Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 349, 454–457 (1997).
  • Degli Esposti L, Degli Esposti E, Valpiani G et al A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 24(8), 1347–1357 (2002).
  • •Refer to Giorgio Valpiani for further comments on the paper ([email protected]).
  • Caro JJ, Salas M, Speakman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. Can. Med. Assoc.1. 160, 31–37 (1999).
  • ••Key reference on the burden of nonpersistence with antihypertensive pharrnacotherapy.
  • McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med. Cam 32, 214–226 (1994).
  • Skaer TL, Sclar DA, Robinson LM. Noncompliance with antihypertensive therapy: economic consequences. PharmacoEconomics9(1), 1–4 (1996).
  • Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch. Intern. Med. 150, 841 (1990).
  • Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L. Using healthcare claims data for outcome research and pharmacoeconomic analyses. PharmacoEconomics 16, 1–8 (1999).
  • •Useful paper on the use of healthcare claims databases for outcome research.
  • Quam L, Ellis LBM, Venus P et al Using claims data for epidemiologic research. Med. Cam 31(6), 498–507 (1993).
  • Mitchell JB, Bubolz T, Paul JE et al Using Medicare claims for outcome research. Med. Care 32(7 Suppl.), JS38—JS51 (1994).
  • Degli Esposti E, Sturani A, Degli Esposti L et al Pharmacoutilization of antihypertensive drugs: a model of analysis. kzLj Gun. Pharmacol Ther 39, 251–258 (2001).
  • Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). The sixth report of the JNC VI. Arch. Intern Med 157, 2413–2446 (1997).
  • Motheral BR, Fairman IKA. The use of claims databases for outcome research: rational challenges and strategies. Clin. Ther. 19(2), 346–366 (1997).
  • ••Really interesting reference for pros andcons of using healthcare claims databases for outcome research.
  • Relman AS. Assessment and accountability. The third revolution in medical care. N Engl. I Med. 319(18), 1220–1222 (1998).
  • ••Provides an interesting overview of healthcare systems evolution in the last decades.
  • Black N. Developing high quality clinical databases. BE Med 315(7119), 1323–1324 (1997).
  • ••Editorial debating the lack of powerfuldatabases and the usefulness of information.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.